Abstract
Introduction: The post-treatment monitoring of glioma patients remains an area of active research and development. Conventional imaging with MRI is a highly sensitive modality for detecting and monitoring primary and secondary brain tumors and includes multi-parametric sequences to better characterize the disease. Standardized schemes for measuring response to treatment are in wide clinical use; however, the introduction of new therapeutics have introduced new patterns of response that can confound interpretation of conventional MRI and can cause uncertainty in the proper management following therapy. Areas covered: A summary of current and evolving techniques for assessing glioma response in this era of new therapies that address these challenges are presented in this review. While this review focuses more on clinical and early clinical methodologies for MRI and nuclear medicine techniques some promising pre-clinical techniques are also presented. Expert commentary: While successful single institution results have been widely reported in the literature, any new methodologies must be undertaken in multi-center settings. Additionally, the need for standardization of protocols in quantitative measured are an important area that must be addressed for new and promising techniques to be implemented to a wide array of patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1177-1188 |
| Number of pages | 12 |
| Journal | Expert Review of Anticancer Therapy |
| Volume | 16 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 1 2016 |
Fingerprint
Keywords
- Glioma
- MRI
- concurrent radiochemotherapy
- glioblastoma
- pseudoprogression
- pseudoresponse
ASJC Scopus subject areas
- Oncology
- Pharmacology (medical)
Cite this
Detecting tumor progression in glioma : current standards and new techniques. / Belliveau, Jean Guy; Bauman, Glenn; Macdonald, David R.
In: Expert Review of Anticancer Therapy, Vol. 16, No. 11, 01.11.2016, p. 1177-1188.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Detecting tumor progression in glioma
T2 - current standards and new techniques
AU - Belliveau, Jean Guy
AU - Bauman, Glenn
AU - Macdonald, David R.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Introduction: The post-treatment monitoring of glioma patients remains an area of active research and development. Conventional imaging with MRI is a highly sensitive modality for detecting and monitoring primary and secondary brain tumors and includes multi-parametric sequences to better characterize the disease. Standardized schemes for measuring response to treatment are in wide clinical use; however, the introduction of new therapeutics have introduced new patterns of response that can confound interpretation of conventional MRI and can cause uncertainty in the proper management following therapy. Areas covered: A summary of current and evolving techniques for assessing glioma response in this era of new therapies that address these challenges are presented in this review. While this review focuses more on clinical and early clinical methodologies for MRI and nuclear medicine techniques some promising pre-clinical techniques are also presented. Expert commentary: While successful single institution results have been widely reported in the literature, any new methodologies must be undertaken in multi-center settings. Additionally, the need for standardization of protocols in quantitative measured are an important area that must be addressed for new and promising techniques to be implemented to a wide array of patients.
AB - Introduction: The post-treatment monitoring of glioma patients remains an area of active research and development. Conventional imaging with MRI is a highly sensitive modality for detecting and monitoring primary and secondary brain tumors and includes multi-parametric sequences to better characterize the disease. Standardized schemes for measuring response to treatment are in wide clinical use; however, the introduction of new therapeutics have introduced new patterns of response that can confound interpretation of conventional MRI and can cause uncertainty in the proper management following therapy. Areas covered: A summary of current and evolving techniques for assessing glioma response in this era of new therapies that address these challenges are presented in this review. While this review focuses more on clinical and early clinical methodologies for MRI and nuclear medicine techniques some promising pre-clinical techniques are also presented. Expert commentary: While successful single institution results have been widely reported in the literature, any new methodologies must be undertaken in multi-center settings. Additionally, the need for standardization of protocols in quantitative measured are an important area that must be addressed for new and promising techniques to be implemented to a wide array of patients.
KW - Glioma
KW - MRI
KW - concurrent radiochemotherapy
KW - glioblastoma
KW - pseudoprogression
KW - pseudoresponse
UR - http://www.scopus.com/inward/record.url?scp=84991579784&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84991579784&partnerID=8YFLogxK
U2 - 10.1080/14737140.2016.1240621
DO - 10.1080/14737140.2016.1240621
M3 - Review article
AN - SCOPUS:84991579784
VL - 16
SP - 1177
EP - 1188
JO - Expert Review of Anticancer Therapy
JF - Expert Review of Anticancer Therapy
SN - 1473-7140
IS - 11
ER -